Arecor Therapeutics (LON:AREC) Trading Down 0.3% – Here’s What Happened

Shares of Arecor Therapeutics plc (LON:AREC) fell 0.3% during trading on Thursday . The company traded as low as GBX 85.26 and last traded at GBX 85.26. Approximately 1,182 shares changed hands during trading, a decline of 95% from the average daily volume of 24,282 shares. The stock had previously closed at GBX 85.50.

Arecor Therapeutics Stock Performance

The company has a current ratio of 4.35, a quick ratio of 6.24 and a debt-to-equity ratio of 1.52. The firm’s 50-day moving average is GBX 67.69 and its two-hundred day moving average is GBX 67.10. The stock has a market cap of £32.19 million, a price-to-earnings ratio of 42.63 and a beta of -0.18.

About Arecor Therapeutics

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.